|Articles|July 27, 2017

ICON Acquires Mapi Group

ICON plc-a global provider of drug development solutions and services to the pharmaceutical, biotechnology, and medical device industries-announced it has acquired the patient-centered health outcomes research and commercialization company, Mapi Group.

Read the full release here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related Content

Why Payment Performance Has Become a Competitive Differentiator for Sponsors

ByPatrick Mizer,Andy Studna, Senior Editor

August 24th 2026

Speed, Discipline, and the New Rules of Biotech Development: Q&A with Stella K. Vnook, PhD, Kaida BioPharma and Aviva Ventures

ByStella K. Vnook, PhD,Andy Studna, Senior Editor

August 24th 2026

ACT Brief: AI Literacy and Ecosystem Adoption Requirements, CRO Operating Models Under Agentic AI Pressure, and Platform Collaborations in Vaccine and Antibody Discovery

ByAndy Studna, Senior Editor

August 24th 2026

When the Slack Runs Out: AI and the CRO Operating Model

ByJoanna Williams

August 21st 2026

What Needs to Be True Across Sponsors, Sites, and Regulators for Operation TrialBlazer to Succeed

ByAmber Hill, PhD,Andy Studna, Senior Editor

August 21st 2026

Trending on Applied Clinical Trials Online

Curavit Acquires Lindus Health Clinical Research Organization Assets to Expand US and European Trial Operations

When the Slack Runs Out: AI and the CRO Operating Model

ACT Brief: Trial Failures as Administrative Problems, CRO Consolidation for Global Trial Reach, and FDA Approval of First FOP Treatment

What Needs to Be True Across Sponsors, Sites, and Regulators for Operation TrialBlazer to Succeed

Speed, Discipline, and the New Rules of Biotech Development: Q&A with Stella K. Vnook, PhD, Kaida BioPharma and Aviva Ventures